CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Fluoxetine 20 MG Oral Tabletdrug
Likely dose
Fluoxetine 20 MG Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03728153
NCT03728153Phase 2Completed
CompareCT.gov

MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania

Massachusetts General Hospital·interventional·Posted Nov 1, 2018·Updated May 25, 2022

In Brief

A Phase 2 clinical trial evaluating Fluoxetine 20 MG Oral Tablet for Acute Stroke and Stroke, Ischemic. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This is a phase II, randomized study of 120 adults age 18 or above who will prescribed 20mg daily Fluoxetine for 90 days following acute, ischemic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Stroke, Stroke, Ischemic
CountriesTanzania
CollaboratorsMuhimbili University of Health and Allied Sciences

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 1, 2018
Enrollment StartNov 26, 2019
Primary CompletionJan 6, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.7 years ago

Interventions

Fluoxetine 20 MG Oral Tabletdrug

Once-daily dosing for 90 days